| Inverness Medical Innovations to Attend the Jefferies 2010 Global Life Sciences Conference on June 8, 2010 (PR Newswire) Inverness Medical Innovations, Inc. , a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced today that it will attend the Jefferies 2010 Global Life Sciences Conference being held June 8 through 11, 2010 at the Grand Hyatt, New York, New York. us.rd.yahoo.com |
Biogen Tops Estimates, Raises Guidance on Strong Pipeline Zacks.com submits: Biogen Idec Inc. (BIIB) reported second-quarter earnings per share of $1.27, well above the Zacks Consensus Estimate of $1.08 and the year-earlier figure of 73 cents. Excluding the impact of stock-based compensation expense, second quarter 2010 earnings came in at $1.31 per share. Performance was boosted by higher revenues. Revenues increased 11% to $1.2 billion, with Tysabri and Rituxan being the primary growth drivers. Revenue by Major ProductsComplete Story » seekingalpha.com |
WellCare Settles Litigation WellCare swung to a second-quarter loss as it announced the settlement of litigation related to a past accounting scandal. online.wsj.com |
Court Ruling Increases Pressure on Sanofi to Buy Genzyme The Burrill Report submits: By Michael Fitzhugh Sanofi-Aventis (SNY) has lost a legal battle intended to fend off generic competition for Taxotere, a cancer medicine that generated more than 8 percent of its net pharmaceutical sales in 2009. The U.S. District Court ruling invalidates two patents that would have protected Taxotere from generic competition until 2013. Hospira and Apotex, two companies planning to market generic versions of the drug, will be happy to get rolling sooner than that. But for Sanofi, the ruling could have larger implications. Accelerated competition for Taxotere could erode revenue sooner than expected, ratcheting up the pressure to replace it by acquiring Genzyme (GENZ). Genzyme's board rebuffed Sanofi's August offer of $69 per share as too meagerly priced. But already rumors of Sanofi's intentions to raise that bid have surfaced. Sanofi's board could meet within days to approve a higher bid for Genzyme, according to Dow Jones Newswires. A higher bid could prompt Genzyme to allow Sanofi access to confidential financial information on its books and conduct due diligence on the company. Complete Story » seekingalpha.com |
4 Biotech Growth Stocks at a Reasonable Price Benzinga submits: By Scott RubinA screen of biotechnology stocks focusing on strong revenue growth and reasonable valuations turned up some interesting, and widely followed, names. The metrics the screen used were Nasdaq and NYSE companies in the drugs and biotechnology sector that had a market capitalization over $1 billion, revenue growth between 15-25% year over year, a P/E ratio less than 20 and a PEG ratio less than 2.Complete Story » seekingalpha.com |